Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users question effectiveness of HMI-115 and consider waiting longer for results.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The conversation discusses the cost and insurance coverage of a comprehensive hormone and DHT blood panel for hair loss, with a focus on finasteride treatment. The user seeks a cheaper alternative to a $700 panel recommended in a video.
The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.
A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.
The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.
The conversation is about experiences with GHK-Cu Copper and AHK-Cu Copper for hair regrowth and thickening. One user expressed skepticism about its effectiveness.
The conversation is about hair transplants in America, specifically the availability of DHI. The user is currently using finasteride and plans to use microneedling, oral castor oil, and eventually undergo FUE or DHI.
A user named "LordGeek101" shared their positive experience with hair regrowth after using 5mg of finasteride daily, 5% minoxidil twice daily, and hormone replacement therapy (HRT) for 8 months. The user is transgender (MTF) and mentioned that the larger dose of finasteride was recommended by their doctor for better chances of hair revival.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
A user discussed a significant hair recovery using alfatradiol and fluridil but was considered untrustworthy and the post was deleted. They are seeking the original poster's username.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The conversation discusses starting finasteride 1mg daily for hair loss and mentions a high baseline DHT level. Users comment on the unusually high DHT level and its potential causes.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.